Tixagevimab - CISMeF

Preferred Label : Tixagevimab;

NCIt definition : A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : F0LZ415Z3B;

CAS number : 2420564-02-7;

Molecule name : AZD 8895; COV2-2196; AZD-8895;

NCI Metathesaurus CUI : CL1642820;

Details

Origin ID

C177082;

UMLS CUI

C5432264;

Currated CISMeF NLP mapping
- Tixagevimab [SMS substance]
- tixagevimab [MeSH Supplementary Concept]
- tixagevimab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- tixagevimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients